SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Genmab: Rinatabart Sesutecan Shows Durable Responses in Ovarian Cancer Trial

Genmab announced results from Part C of the Phase 1/2 RAINFOL™-01 trial for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer. The investigational drug demonstrated durable and clinically meaningful responses among 109 treated patients.

GMAB

Story updates

07:41:08 PM UTC
SquawkNews
Genmab reported Rina-S achieved a confirmed 45.9% ORR and 12.1-month mDOR in 109 platinum—resistant ovarian cancer patients; mPFS was 9.5 months. Activity was seen regardless of FRα expression and prior mirvetuximab.Material DetailsContext by AI AnalystThis is a mid-stage efficacy update that stren…

Related stories